Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3293 of 3318  at  9/9/2020 7:41:44 PM  by

BSR_Alan

The following message was updated on 9/9/2020 8:13:37 PM.

 In response to msg 3292 by  i760
view thread

Re: Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow

You think that 12 wks dosing is long enough to see impact ? My expectation was it might take a bit longer to fully show the drug effect, so that makes me lower probability a bit.
  
I also expect an extension study...if all proceeds well. 
 
Like the previous metabolic trials, Corcept isn't aiming for statistical significance (they got it anyways). Three months should be enough to see the changes in the markers. Will Miricorilant have enough time to reduce pathogenic fat in the liver? Everything else will follow: inflammatory markers, MRI scans, fibrotic markers, etc. 
 
Looking at the prior drug trials with AIWG, this should be enough time between miricorilant versus placebo groups on just about every marker. The gamble is whether it's enough time for the MRI scans. In the conference calls, Belanoff referred discussion about the 900mg AIWG group to the publication.
 
Remember the surprising result? Miricorilant aided liver health. Corcept and its investigators can map the results to specific patients. I will bet that it was the "obese normals" that experienced the most benefit. 
 
With NASH patients, some should be pretty darn obese. This should be an interesting test of miricorilant's ability to realign the HPA system (AKA Cortisol System Overdrive). 
 
Corcept has been receiving data about Cushing's and Adrenal Adenoma patients resolve their liver problems with Korlym and relacorilant. 
  
Also I was expecting a longer follow-up, but maybe they will do that if they see a good initial effect by offering an extension study.
 
If it goes well, I'd be surprised if there wasn't an extension. They might as well put the placebo patients on miricorilant and collect additional data. Corcept should also want the longer-term safety data.
 
Lastly if it is just 120 subjects and a 3 month trial in NASH why are they projecting 18 months to completion. NASH is no orphan disease and unless they are deliberately going at old Corcept slow speed, they should be able to wrap up the trial in less than a year.
 
I noticed the AIWG trials were projected slower, largely because of COVID. I think the same goes for NASH.  Everyone and their brother is clogging up university pipelines with NASH trials with interesting and worthless drugs.
 
At the same time, Universities were charging more and moving slower. This was already occurring before COVID. I heard the complaints from various teams in 2018-19.

And now? I can't see that it got any better.
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 102
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
3294 Re: Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow i760 2 9/9/2020 10:11:14 PM






Financial Market Data provided by
.


Loading...